Application of L-EDA in metabonomics data handling: global metabolite profiling and potential biomarker discovery of epithelial ovarian cancer prognosis

Metabolomics ◽  
2011 ◽  
Vol 7 (4) ◽  
pp. 614-622 ◽  
Author(s):  
Jing Chen ◽  
Yang Zhang ◽  
Xiaoyan Zhang ◽  
Rui Cao ◽  
Shili Chen ◽  
...  
Author(s):  
Priya Paliwal ◽  
Hemangi Ranade ◽  
Dignya Desai ◽  
Manali Datta

: Epithelial ovarian cancer (EOC) is a chronic and degenerative disease propelled by mutation in BRCA1/2 genes, familial history, smoking and polycystic ovary syndrome. Although lifetime risk of ovarian cancer is low, yet it is the fifth leading cause of cancer related deaths. Surprisingly, EOC represents 90% of all ovarian cancers, out of which 70% women are diagnosed with the malignancy at its advanced III-IV stages. Early detection may increase the life expectancy up to 5 years. Thus, it has become need of the hour to attain improvement of clinical outcomes of EOC and improve life expectancy of patients. Plethora of proteins in different biological fluids may serve as prospective identifiers for the disease. Over the years, accurate identification of proteins secreted by EOC cells has been perfected by in vitro and in silico state of art technologies. Multivariate test, consisting of histo-pathological data in combination with protein biomarker panel has paved way for enhanced and accurate assessment for EOC, still there is a chance of further improvement. This review encompasses the inputs made in ovarian cancer biomarker discovery and demonstrates their potential usefulness for design of early diagnostics of EOC.


Oncotarget ◽  
2016 ◽  
Vol 8 (12) ◽  
pp. 18773-18791 ◽  
Author(s):  
Michael Kleemann ◽  
Jeremias Bereuther ◽  
Simon Fischer ◽  
Kim Marquart ◽  
Simon Hänle ◽  
...  

2019 ◽  
Vol 11 (3) ◽  
pp. 267-72
Author(s):  
Addin Trirahmanto ◽  
Hariyono Winarto ◽  
Aria Kekalih ◽  
Ferry Sandra

BACKGROUND: Ovarian cancer is the 8th most prevalent cancer in women in the world. Current biomarker prognosis for ovarian cancer has numerous limitations, thus new biomarkers are needed. MicroRNAs (miRs) are considered as potential biomarkers in ovarian cancer as they are stable in blood. One candidate is miR-200c, the main regulator in epithelial transition to the mesenchyme. The aim of this study is to determine the role of miR-200c as prognostic biomarker for epithelial ovarian cancer (EOC).METHODS: This is a prospective cohort study conducted at Dr. Sardjito Central General Hospital in Yogyakarta from September 2015 to July 2018. Sampling was done using consecutive sampling method. Forty plasma samples of EOC subjects were included in this study. miR-200c expression was quantified using Reverse Transcriptase Quantitative Quantitative Polymerase Chain Reaction (RTqPCR) with miR-16 as the reference gene.RESULTS: The expression of miR-200c was significantly higher in the group of subjects with preoperative CA-125 levels >500 U/mL (p=0.009) than the group of subjects with preoperative CA-125 levels <500 U/mL. Subjects with higher miR-200c expression had lower survival rate than subjects with lower miR-200c expression, although not statistically significant.CONCLUSION: The miR-200c could be a promising biomarker for EOC. Further studies with larger sample sizes are needed to clarify the prognostic value of miR200c.KEYWORDS: miR-200c, epithelial ovarian cancer, prognosis, overall survival


2021 ◽  
pp. 1-6
Author(s):  
Liming Fan ◽  
Hualiang Yang ◽  
Bo Zhang ◽  
Hong Ding

PURPOSE: To propose MCUR1 gene as a potential biomarker for ovarian cancer prognosis. METHODS: The ovarian cancer patient specimen from TCGA database were analyzed using survival analysis. The immune cell infiltration ratio and checkpoints had also been investigated for different expression group of MCUR1. The function of MCUR1 as a ovarian cancer prognosis biomarker was verified in clinic. RESULTS: The low expression of MCUR1 was associated with the poor prognosis of ovarian cancer patients. The expressions of majority of immune cells and 6 checkpoints in low expression group of MCUR1 were significantly lower than that in high expression group of MCUR1 (P< 0.05). The MCUR1 could be utilized as a prognostic biomarker for ovarian cancer patients in clinic. CONCLUSION: This study has proposed a potential prognostic biomarker for ovarian cancer patients, which offers a beneficial reference for future ovarian cancer administration.


2016 ◽  
Vol 141 (1) ◽  
pp. 121-127 ◽  
Author(s):  
Lingeng Lu ◽  
Dionyssios Katsaros ◽  
Emilie Marion Canuto ◽  
Nicoletta Biglia ◽  
Harvey A. Risch ◽  
...  

2018 ◽  
Vol 19 (10) ◽  
pp. e507
Author(s):  
Melissa A Merritt ◽  
Shelley S Tworoger

Sign in / Sign up

Export Citation Format

Share Document